Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
A cooling of the M&A climate allows Asia-based groups to come to the fore.
Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.